Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: Why they are needed and how they might work

Influenza and other Respiratory Viruses

Volumn 3, Issue 4, 2009, Pages 129-142

  Fedson, David S ^a  

^a NONE   (France)

Author keywords

Host response; Influenza; Pandemic; Peroxisome proliferator activator receptor agonists; Statins

Indexed keywords

AMPICILLIN; ANTIINFLAMMATORY AGENT; AZITHROMYCIN; CATECHIN; CELECOXIB; CHLOROQUINE; CLINDAMYCIN; CURCUMIN; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOMODULATING AGENT; INFLUENZA VACCINE; MESALAZINE; METFORMIN; OSELTAMIVIR; PIOGLITAZONE; RESVERATROL; ROSIGLITAZONE; SIMVASTATIN; ZANAMIVIR;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; AGE DISTRIBUTION; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; AUTOPHAGY; BACTERIAL PNEUMONIA; BACTERIAL SUPERINFECTION; BRAIN MALARIA; BURN; CLINICAL TRIAL; CYTOKINE RELEASE; DIABETES MELLITUS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BLOOD LEVEL; DRUG COST; HEALTH CARE PLANNING; HEART INFARCTION; HUMAN; IMMUNOMODULATION; INFLUENZA; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H5N1; LIVER ISCHEMIA; MORTALITY; MULTIPLE ORGAN FAILURE; NONHUMAN; PANDEMIC; PLEIOTROPY; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; REPERFUSION INJURY; RESEARCH PRIORITY; REVIEW; SECONDARY INFECTION; SEPSIS; SERRATIA INFECTION; SURVIVAL RATE; VIRUS VIRULENCE;

ACUTE LUNG INJURY; ANTI-INFLAMMATORY AGENTS; DISEASE OUTBREAKS; HUMANS; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN;

EID: 67649126476     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2009.00090.x     Document Type: Review

References (122)

1. Thomas L. Lives of a Cell. Notes of a Biology Watcher. New York: Penguin Books, 1974, pp 78-79.
2. Peiris JS, de Jong MD, Guan Y. Avian influenza A (H5N1): A threat to human health. Clin Microbiol Rev 2007; 20:243-267.
3. Gambotto A, Barratt-Boyes SM, de Jong MD, Neumann G, Kawaoka Y. Human infection with highly pathogenic H5N1 influenza virus. Lancet 2008; 371:1464-1475.
4. Kortweg C, Gu J. Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol 2008; 172:1155-1170.
5. Maines TR, Szretter KJ, Perrone L et al. Pathogenesis of emerging avian influenza viruses in mammals and the host innate immune response. Immunol Rev 2008; 225:68-84.
6. Basler CF, Aguilar PV. Progress in identifying virulence determinants of the 1918 H1N1 and Southeast Asian H5N1 influenza A viruses. Antiviral Res 2008; 79:166-178.
7. Salomon R, Webster RG. The influenza virus enigma. Cell 2009; 136:402-410.
8. Palache B, Krause R. Progress with human H5N1 vaccines: A perspective from industry. Exp Rev Vaccines 2009; 8:375-400.
9. Leroux-Roels I, Leroux-Roels G. Current status and progress of pre-pandemic and pandemic influenza vaccine development. Exp Rev Vaccines 2009; 8:401-423.
10. Jennings L, Monto AS, Chan PKS, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: A new cornerstone of pandemic preparedness plans. Lancet Infect Dis 2008; 8:650-658.
11. Fedson DS, Dunnill P. From scarcity to abundance: Pandemic vaccines and other agents for 'have not' countries. J Public Health Policy 2007; 28:322-340.
12. Fedson DS. New technologies for meeting the global demand for pandemic influenza vaccines. Biologicals 2008; 36:346-349.
13. News Release. International Federation of Pharmaceutical Manufacturers Associations. Authoritative New Study Reveals Global Pandemic Influenza Vaccine Capacity. Available on: http://www.ifpma.org (Accessed 24 February 2009).
14. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: Can it be done? Lancet Infect Dis 2008; 8:571-576.
15. Fedson DS. Meeting the challenge of influenza pandemic preparedness in developing countries. Emerg Infect Dis 2009; 15:365-371.
16. Webster RG, Campbell CH. Studies on the origin of pandemic influenza. IV. Selection and transmission of 'new' influenza viruses in vivo. Virology 1974; 62:404-413.
17. Baskin CR, Bielefeldt H, Tumpey TM et al. Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci USA 2009; 106:3455-3460.
18. Writing Committee of the Second World Health Organization Consultation on clinical aspects of human infection with avian influenza A (H5N1) virus: Update on avian influenza A (H5N1) virus infection in humans. New Engl J Med 2008; 358:261-273.
19. de Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12:1203-1207.
20. Morens DM, Taubenberger JF, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: Implications for pandemic influenza preparedness. J Infect Dis 2008; 198:962-970.
21. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19:571-582.
22. Morens DM, Taubenberger JK, Fauci AS. Commentary on fatalities in the 1918-1919 influenza pandemic. J Infect Dis 2009; 199:913-914.
23. Fedson DS. Was bacterial pneumonia the predominant cause of death in the 1918-1919 influenza pandemic? J Infect Dis 2009; 199:1408-1409.
24. Brundage JF, Shanks GD. Death from bacterial pneumonia during 1918-19 influenza pandemic. Emerg Infect Dis 2008; 8:1193-1199.
25. Ahmed R, Oldstone MBA, Palese P. Protective immunity and susceptibility to infectious diseases: Lessons from the 1918 influenza pandemic. Nat Immunol 2006; 11:1188-1193.
26. Leenstra T, ter Kuile FO, Kariuki SK et al. Dehydroepiandrosterone sulfate levels associated with decreased malaria parasite density and increased hemoglobin concentration in pubertal girls from western Kenya. J Infect Dis 2003; 188:297-304.
27. Kurtis JD, Friedman JF, Leenstra T et al. Pubertal development predicts resistance to infection and reinfection with Schistosoma japonicum. Clin Infect Dis 2006; 42:1092-1098.
28. Clark IA, Alleva LM, Budd AC, Cowden WB. Understanding the role of inflammatory cytokines in malaria and related diseases. Travel Med Infect Dis. 2008; 6:67-81.
29. Clark IA, Budd AC, Alleva LM. Sickness behaviour pushed too far -the basis for the syndrome seen in severe protozoal, bacterial and viral diseases and post-trauma. Malaria J 2008; 7:208.
30. Bianchi ME. DAMPs, PAMPs and alarmins: All we need to know about danger. J Leukoc Biol 2007; 81:1-5.
31. Fedson DS. Pandemic influenza: A potential role for statins in treatment and prophylaxis. Clin Infect Dis 2006; 43:199-205.
32. Zheng BJ, Chan KW, Lin YP et al. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 2008; 105:8091-8096.
33. Simmons C, Farrar JT. Insights into inflammation. N Engl J Med 2008; 359:1621-1623.
34. Tsatanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 2006; 38:1654-1661.
35. Fukunaga K, Kohli P, Bonnans C, Fredenburgh LE, Levy BD. Cyclooxygenase 2 plays a pivotal role in the resolution of acute lung injury. J Immunol 2005; 174:5033-5039.
36. Rousseaux C, Lefebvre B, Dubuquoy L et al. Intestinal anti-inflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005; 201:1205-1215.
37. Karlstrom A, Boyd KL, English BK, McCullers JA. Treatment with protein synthesis inhibitors improves outcomes of secondary bacterial pneumonia after influenza. J Infect Dis 2009; 199:311-319.
38. Tamaoki J, Kadota J, Takizawa H. Clinical implications of the immunomodulatory effects of macrolides. Am J Med 2004; 117(Suppl. 9A):5S-11S.
39. Hodge S, Hodge G, Brozyna S, Jersmann H, Holmes M, Reynolds PN. Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages. Eur Respir J 2006; 28:486-495.
40. Sugiyama K, Shirai R, Mukae H et al. Differing effects of clarithromycin and azithromycin on cyokine production in murine dendritic cells. Clin Exp Immunol 2007; 147:540-546.
41. Hodge S, Hodge G, Jersmann H et al. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 178:139-148.
42. Imai Y, Kuba K, Neely GG et al. Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 2008; 133:235-249.
43. Nakahira K, Kim HP, Geng XH et al. Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. J Exp Med 2006; 203:2377-2389.
44. Ryter SW, Kim HP, Nakahira K, Zuckerbraun BS, Morse D, Choi AM. Protective functions of heme oxygenase-1 and carbon monoxide in the respiratory system. Antioxid Redox Signal 2007; 9:2157-2173.
45. Chung SW, Liu X, Macias AA, Baron RM, Perrella MA. Heme-oxygenase-1-derived carbon monoxide enhances the host defense response to microbial sepsis in mice. J Clin Invest 2008; 118:239-247.
46. Chaturvedi A, Pierce SK. How location governs Toll-like receptor signaling. Traffic 2009; 10:621-628.
47. Soares MP, Bach FH. Heme oxygenase-1: From biology to therapeutic potential. Trends Mol Med 2009; 15:50-57.
48. Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med 2008; 358:716-727.
49. Mizgerd JP, Skerrett SJ. Animal models of human lung disease. Am J Physiol Lung Cell Mol Physiol 2008; 294:L387-L398.
50. Hotchkiss RS, Nicholson DW. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006; 6:813-822.
51. van der Poll T, Opal SM. Host-pathogen interactions in sepsis. Lancet Infect Dis 2008; 8:32-43.
52. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008; 8:776-787.
53. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA. Tilting toward immunosuppression. Nat Med 2009; 15:496-497.
54. Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2007; 14:37-44.
55. Terblanche M, Almog Y, Rosenson RS, Smith TS, Hackam DG. Statins and sepsis: Multiple modifications at multiple levels. Lancet Infect Dis 2007; 7:358-368.
56. Choi HS, Park MJ, Kang HM, Lim IH, Choi CW, You JH. Statin use and mortality in sepsis due to pneumonia (abstract). Crit Care Med 2007; 35(Suppl. 12):1362.
57. Dyson A, Singer M. Animal models of sepsis: Why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med 2009; 37(Suppl. 1):S30-S37.
58. Kruger PS, Freir NM, Venkatesh B, Robertson TA, Roberts MS, Jones MA. Preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med 2009; 35:717-721.
59. Straus DS, Glass CK. Anti-inflammatory actions of PPAR ligands: New insights on cellular and molecular mechanisms. Trends Immunol 2007; 28:551-558.
60. Smith MR, Standiford TJ, Reddy RC. PPARs in alveolar macrophage biology. PPAR Res 2007; 2007:23812.
61. Yano MY, Matsumura T, Senokuchi T et al. Statins activate peroxisome proliferator-activated receptorγ through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooygenase-2 expression in macrophages. Circ Res 2007; 100:1442-1451.
62. Paulmelle R, Staels B. Cross-talk between statins and PPAR in cardiovascular diseases: Clinical evidence and basic mechanisms. Trends Cardiovasc Med 2008; 18:73-78.
63. Inoue I, Itoh F, Aoyagi S et al. Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB. Biochem Biophys Res Commun 2002; 290:131-139.
64. Birnbaum Y, Ye Y, Lin Y et al. Augmentation of myocardial production of 15-epi-lipoxin-A4 by pioglitazone and atorvastatin in the rat. Circulation 2006; 114:929-935.
65. Budd A, Alleva L, Alsharifi M et al. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 2007; 51:2965-2968.
66. Aldridge JR, Moseley CE, Boltz DA et al. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci USA 2009; 106:5306-5311.
67. Lin KL, Suzuki Y, Nakano H, Ramsburg E, Gunn MD. CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced immune pathology and mortality. J Immunol 2008; 180:2562-2572.
68. Pamer EG. Tipping the balance in favor of protective immunity during influenza virus infection. Proc Natl Acad Sci USA 2009; 106:4961-4962.
69. Han KH, Ryu J, Hong KH et al. HMG-CoA reductase inhibition reduces monocyte CC chemokine receptor 2 expression and monocyte chemoattractant protein-1-mediated monocyte recruitment in vivo. Circulation 2005; 111:1439-1447.
70. Veillard NR, Braunersreuther V, Arnaud C et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006; 188:51-58.
71. Palamara AT, Nencioni L, Aquilano K et al. Inhibition of influenza A virus replication by resveratrol. J Infect Dis 2005; 191:1719-1729.
72. Cho IJ, Ahn JY, Kim S, Choi MS, Ha TY. Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters. Biochem Biophys Res Comm 2008; 367:190-194.
73. Inoue H, Jiang XF, Katayama T, Osada S, Umesono K, Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci Lett 2003; 352:203-206.
74. Ge H, Zhang JF, Guo BS et al. Resveratrol inhibits macrophage expression of EMMPRIN by activating PPARgamma. Vascul Pharmacol 2007; 46:114-121.
75. Penumathsa SV, Thirunavukkarasu M, Koneru S et al. Statin and resveratrol in combination induces cardioprotection against myocardial infarction in hypercholesterolemic rat. J Mol Cell Cardiol 2007; 42:508-516.
76. Donnelly LE, Newton R, Kennedy GE et al. Anti-inflammatory effects of resveratrol in lung epithelial cells: Molecular mechanisms. Am J Physiol Lung Cell Mol Physiol 2004; 287:L774-L783.
77. Youn HS, Lee JY, Fitzgerald KA, Young HA, Akira S, Hwang DH. Specific inhibition of My88-independent signaling pathways of TLR3 and TLR4 by resveratrol: Molecular targets are TBK1 and RIP1 in TRIF complex. J Immunol 2005; 175:3339-3346.
78. Lu CC, Lai HC, Hsieh SC, Chen JK. Resveratrol ameliorates Serratia marcescens -induced acute pneumonia in rats. J Leukoc Biol 2008; 83:1028-1037.
79. Franchi L, Eigenbrod T, Muñoz-Planillo R, Nunez G. The inflammasome: A caspase-1-activation platform that regulates immune response and disease pathogenesis. Nat Immunol 2009; 3:241-247.
80. Allen IC, Scull MA, Moore CB et al. The NLRP3 inflammasome mediates in vivo innate immunity to influenza A virus through recognition of viral RNA. Immunity 2009; 30:556-565.
81. Thomas PG, Dash P, Aldridge JR Jr et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via regulation of caspase-1. Immunity 2009; 30:566-575.
82. Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med 2009; 206:79-87.
83. Owen DM, Gale M. Fighting flu with inflammasomes signalling. Immunity 2009; 30:476-478.
84. Frahy RJ, Exline MC, Gavrillin MA et al. Inflammasome mRNA expression in human monocytes during early septic shock. Am J Respir Crit Care Med 2008; 177:983-988.
85. Coward WR, Marei A, Yang AL, Vasa-Nicotera MM, Chow SC. Statin-induced proinflammatory response in mitogen-activated peripheral blood mononuclear cells through the activation of caspase-1 and IL-18 secretion in monocytes. J Immunol 2006; 176:5284-5292.
86. Hallett JM, Leitch AE, Riley NA, Duffin R, Haslett C, Rossi AG. Novel pharmacological strategies for driving inflammatory cell apoptosis and enhancing the resolution of inflammation. Trends Pharmacol Sci 2008; 29:250-257.
87. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451:1069-1075.
88. Hsieh YC, Athar M, Chaudry IH. When apoptosis meets autophagy: Deciding cell fate after trauma and sepsis. Trends Mol Med 2009; 15:129-138.
89. Zhou Z, Jiang X, Liu D et al. Autophagy is involved in influenza A virus replication. Autophagy 2009; 5:321-328.
90. Mok CKP, Lee DCW, Cheung CY, Peiris M, Lau ASY. Differential onset of apoptosis in influenza A virus H5N1- and H1N1-infected human blood macrophages. J Gen Virol 2007; 88:1275-1280.
91. Daidoji T, Koma T, Du A et al. H5N1 avian influenza virus induces apoptotic cell death in mammalian airway epithelial cells. J Virol 2008; 82:11295-11307.
92. Lam WY, Tang JW, Yeung AC, Chiu LC, Sung JJ, Chan PK. Avian influenza virus A/HK/483/97 (H5N1) NS1 protein induces apoptosis in human airway epithelial cells. J Virol 2008; 82:2741-2751.
93. McAuley JL, Hornung F, Boyd KL et al. Expression of the 1918 influenza A virus PB1-F2 enhances the pathogenesis of viral and secondary bacterial pneumonia. Cell Host Microbe 2007; 2:240-249.
94. Uiprasertkul M, Kitphati R, Puthavanthana P et al. Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans. Emerg Infect Dis 2007; 13:708-712.
95. Buerke U, Carter JM, Schlitt A et al. Apoptosis contributes to septic cardiomyopathy and is improved by simvastatin therapy. Shock 2008; 29:497-503.
96. Lai IR, Chang KJ, Tsai HW, Chen CF. Pharmacological preconditioning with simvastatin protects liver from ischemia-reperfusion injury by heme-oxygenase-1 induction. Transplantation 2008; 85:732-738.
97. Carre JE, Singer M. Cellular energetic metabolism in sepsis: The need for a systems approach. Biochim Biophys Acta 2008; 1777:763-771.
98. Exline MC, Crouser ED. Mitochondrial mechanisms for sepsis-induced organ failure. Front Biosci 2008; 13:5031-5041.
99. Rasbach KA, Schnellmann RG. Signaling of mitochondrial biogenesis following oxidant lung injury. J Biol Chem 2007; 282:2355-2362.
100. Carraway MS, Suliman HB, Kliment C et al. Mitochondrial biogenesis in the pulmonary vasculature during inhalational lung injury and fibrosis. Antioxid Redox Signal 2008; 10:269-275.
101. Rohas LM, St.-Pierre J, Uldry M, Jager S, Handschin C, Spiegelman BM. A fundamental system of cellular energy homeostasis regulated by PGC-1. Proc Natl Acad Sci USA 2007; 104:7933-7938.
102. Wenz T, Diaz F, Spiegelman BM, Moraes CT. Activation of the PPAR/ PGC-1α pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 2008; 8:249-256.
103. Haden DW, Suliman HB, Carraway MS et al. Mitochondrial biogenesis restores oxidative metabolism during Staphyloccus aureus sepsis. Am J Respir Crit Care Med 2007; 176:768-777.
104. Cote HCF, Day AG, Heyland DK. Longitudinal increases in mitochondrial DNA levels in blood cells are associated with survival in critically ill patients. Crit Care 2007; 11:R88.
105. Suliman HB, Carraway MS, Tatro LG, Piantadosi CA. A new activating role for CO in cardiac mitochondrial biogenesis. J Cell Sci 2007; 120:299-308.
106. Wang YL, Frauwirth KA, Rangwala SM, Lazar MA, Thompson CB. Thiazolidinedione activation of peroxisome proliferator-activated receptorγ can enhance mitochondrial potential and promote cell survival. J Biol Chem 2002; 277:31781-31788.
107. Zmiljewski JW, Lorne E, Zhao X et al. Mitochondrial respiratory complex I regulates neutrophil activation and severity of lung injury. Am J Respir Crit Care Med 2008; 178:168-179.
108. Brunmair B, Staniek K, Gras F et al. Thiozolidinediones, like metformin, inhibit respiratory complex I. A common mechanism contributing to their antidiabetic actions? Diabetes 2004; 53:1052-1059.
109. Brunmair B, Lest A, Staniek K et al. Fenofibrate impairs mitochondrial function by inhibition of respiratory complex I. J Pharmacol Exp Ther 2004; 311:109-114.
110. Rudger A, Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 2007; 35:1599-1608.
111. Hanai J, Cao P, Tanksale P et al. The muscle-specific ubiquitin ligase atrogin-1/MAFbx mediates statin-induced muscle toxicity. J Clin Invest 2007; 117:3940-3951.
112. Cree MG, Zwetsloot JJ, Herndon DN et al. Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate. Ann Surg 2007; 245:214-221.
113. Lowen AC, Mubareka S, Tumpey TM, Garcia-Sastre A, Palese P. The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci USA 2006; 103:9988-9992.
114. Siore AM, Parker RE, Stencenko AA et al. Endotoxin-induced acute lung injury requires interaction with the liver. Am J Physiol Lung Cell Mol Physiol 2005; 289:L769-L776.
115. Calkins CM, Bensard DD, Moore EE et al. The injured child is resistant to multiple organ failure: A different inflammatory response? J Trauma 2002; 53:1058-1063.
116. Finnerty CC, Jeschke MG, Herndon DN et al. Temporal cytokine profiles in severely burned patients: A comparison of adults and children. Mol Med 2008; 14:553-560.
117. Barsness KA, Bensard DD, Partrick DA et al. IL-1β induces an exaggerated pro- and anti-inflammatory response in peritoneal macrophages of children compared with adults. Pediatr Surg Int 2004; 20:238-242.
118. Barsness KA, Bensard DD, Partrick DA, Calkins CM, Hendrickson RJ, McIntryre RC Jr. Endotoxin induces an exaggerated interleukin-10 response in peritoneal macrophages of children compared with adults. J Pediatr Surg 2004; 39:912-915.
119. Shin T, Kuboki S, Huber N et al. Activation of perioxisome proliferator-activated receptor-gamma during hepatic ischemia is age-dependent. J Surg Res 2008; 147:200-205.
120. Di Paola R, Cuzzocrea S. Peroxisome proliferator-activated receptors and acute lung injury. PPAR Res 2007; 2007:63745.
121. Serghides L, Patel SN, Ayi K et al. Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria. J Infect Dis 2009; 199:1536-1545.
122. Opal SM, Patrozou E. Translational research in the development of novel sepsis therapeutics: Logical deductive reasoning or mission impossible? Crit Care Med 2009; 37(Suppl.):S10-S15.